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Abstract
Background: The use of complementary and alternative products including Biological Based
Therapy (BBT) has increased among patients with various medical illnesses and conditions. The
studies assessing the prevalence of BBT use among patients with cardiovascular diseases are
limited. Therefore, an evaluation of BBT in this patient population would be beneficial. This was a
survey designed to determine the effects of demographics on the use of Biological Based Therapy
(BBT) in patients with cardiovascular diseases. The objective of this study was to determine the
effect of the education level on the use of BBT in cardiovascular patients. This survey also assessed
the perceptions of users regarding the safety/efficacy of BBT, types of BBT used and potential BBT-
drug interactions.
Method: The survey instrument was designed to assess the findings. Patients were interviewed
from February 2001 to December 2002. 198 inpatients with cardiovascular diseases (94 BBT users
and 104 non-users) in a university hospital were included in the study.
Results: Users had a significantly higher level of education than non-users (college graduate: 28
[30%] versus 12 [12%], p = 0.003). Top 10 BBT products used were vitamin E [41(43.6%)], vitamin
C [30(31.9%)], multivitamins [24(25.5%)], calcium [19(20.2%)], vitamin B complex [17(18.1%)], fish
oil [12(12.8%)], coenzyme Q10 [11(11.7%)], glucosamine [10(10.6%)], magnesium [8(8.5%)] and
vitamin D [6(6.4%)]. Sixty percent of users' physicians knew of the BBT use. Compared to non-
users, users believed BBT to be safer (p < 0.001) and more effective (p < 0.001) than prescription
drugs. Forty-two potential drug-BBT interactions were identified.
Conclusion: Incidence of use of BBT in cardiovascular patients is high (47.5%), as is the risk of
potential drug interaction. Health care providers need to monitor BBT use in patients with
cardiovascular diseases.
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Background
The use of complementary and alternative medicine
(CAM), defined by the United States National Center for
CAM as a group of diverse medical and health care sys-
tems, practices, and products that are not presently con-
sidered to be a part of conventional medicine, has grown
tremendously in the United States [1-4]. A recent national
survey reported that four out of every ten Americans used
at least one form of CAM, and one out of five used pre-
scription medications together with CAM [3]. The preva-
lence is even higher in patients with chronic medical
problems (for example, 28 to 90% in patients with arthri-
tis, 11–56% in those with cancer, 60% in patients with
asthma and 67.8% in patients with human immunodefi-
ciency virus) [5-11]. Biological based therapies (BBT) is an
important type of CAM and is defined by the National
Center for CAM as use of substances found in nature, such
as herbs, foods, and vitamins. BBT is the second most
commonly utilized CAM, with the first being prayer ther-
apy [2].
Similar to other chronic medical conditions, patients suf-
fering from a variety of cardiovascular diseases including
coronary heart disease, congestive heart failure, stroke,
arrhythmia and congenital cardiovascular defects, may
also be looking to CAM to prevent or treat their illnesses.
This is particularly likely since a number of BBT products
including vitamin E, vitamin C, beta-carotene, fish oils,
and coenzyme Q10 have been evaluated for prevention
and/or treatment of cardiovascular diseases [12-25].
Despite a wide array of available BBT for cardiovascular
conditions, studies evaluating the prevalence of usage of
these agents are limited [21-25]. As CAM, in general, has
become widely accessible to the public, and BBT may be
purchased in pharmacies, health food stores and super-
markets, it is difficult to control patient usage of these
products. In addition, the likelihood for adverse effects
and interactions between conventional therapies and BBT
places patients using such products at an increased risk of
adverse drug events. It is, therefore, important to examine
patient usage so as to advise and monitor them properly.
Among the studies conducted to-date that included
patients with a broad spectrum of cardiovascular diseases,
few focused only on BBT. The studies examined different
factors that may determine BBT use, but none of them
examined the potential for side effects and drug interac-
tions with other prescription and non-prescription medi-
cations that the patients were utilizing. Since patients with
cardiovascular conditions consume many prescription
medications with narrow therapeutic indexes and exten-
sive drug interaction profiles [26,27], it is important to
look at the prevalence of use and potential drug interac-
tions in a cohort of cardiovascular patients.
The primary objective of this study was to determine the
effect of the education level on the use of BBT in cardio-
vascular patients. The study also investigated the attitudes
and beliefs towards BBT by patients with cardiovascular
diseases. In addition, patient perceptions regarding the
safety and efficacy of BBT, common BBT used and a list of
potential BBT-drug interactions were reviewed.
Methods
This is a cross-sectional, descriptive study utilizing struc-
tured interviews to assess the level of education, usage,
beliefs and attitudes towards BBT among inpatients with
cardiovascular diseases. The study was conducted in the
Cardiac Care Center at the Mount Sinai Hospital, New
York, USA from February 2001 to December 2002. Partic-
ipants provided informed consent and were interviewed
by one of the investigators. To maintain consistency of the
interview and to prevent interviewer bias, a scripted letter
was drafted for the investigators to invite the patients to
participate in the study and to explain the process of the
study. After a patient was enrolled, an investigator read
the survey questions verbatim to the patient and tried not
to elaborate whenever possible. Patients were included in
the study if they had at least one of the following diag-
noses: cardiovascular disease(s) including congestive
heart failure, coronary heart disease, thromboembolic dis-
eases, valvular heart disease, arrhythmia, vascular aneu-
rysm, peripheral vascular disease, pulmonary
hypertension, congenital heart disease and post heart
transplant. Additional inclusion criteria included being
18 years of age or older, English speaking, no documented
cognitive deficits precluding the patient from understand-
ing the interviewer, and willingness to provide an
informed consent. Prior to patient contact, the attending
physicians of the eligible patients were contacted and
informed about the study. If the attending physicians
chose not to have their patients participate in the study,
the patients were not included. Upon agreement of the
physicians, subjects were invited to participate and were
asked to sign an informed consent at their convenience
prior to being interviewed. This study was approved by the
Institutional Review Boards of Mount Sinai Hospital and
Long Island University.
Biological based therapy survey
Utilizing a structured instrument (see Additional file 1),
eligible subjects were interviewed by one of the investiga-
tors during their stay at the hospital. The BBT survey was
modified and adapted from a previously published survey
[6]. The participants could choose to answer or not to
answer any question at their discretion, and could discon-
tinue their participation in the study at any time during
the interview. During the interview, demographic data,
including age, gender, race, marital status, level of educa-
tion, annual income, and working status, were collected.BMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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Additionally, history of cardiovascular and other medical
conditions, and medications utilized were recorded. The
definition of BBT in this study was similar to that defined
by the United States National Center for CAM, which
included all herbal supplements, vitamins and mineral
supplements. The patients' attitudes and beliefs towards
BBT were assessed by asking them about their perceived
safety and efficacy of BBT. The side effects and potential
drug/food interactions listed by the patients were com-
pared against those listed in the MicroMedex® Database
[28]. The patients' assessments of benefits of BBT as com-
pared with conventional medicine were recorded. Addi-
tionally, the participants were asked whether they
reported the use of BBT to their physicians, pharmacists,
or other healthcare professionals. A review of patients'
medical records was performed to collect data about
patients' cardiovascular diseases and to confirm medica-
tions used. Although, the identity of the participants in
this research study was kept confidential, patients were
notified in the informed consent process that if potential
BBT-prescription medication interactions were identified,
their physicians would be notified.
Statistical analysis
For this study to have an 80 percent power to detect a 20
percent clinically significant difference in determining fac-
tors of BBT use such as education level between the users
and non-users of BBT, and establishing a p value of < 0.05
as the level of statistical significance, approximately 200
patients (100 patients in each group) needed to be
enrolled. For demographic parameters, continuous varia-
bles were compared between the two groups using Stu-
dents' t-test and categorical variables were compared
using chi-square. Attitudes and beliefs regarding the safety
and efficacy of BBT were compared between the two
groups using a chi-square test for categorical data and Stu-
dents' t test for Likert-type scale questions. The BBT prod-
ucts used by cardiovascular patients were recorded and the
likelihood of potential drug interactions between BBT and
other medications the patients were taking were
described. Statistical analyses were conducted using Statis-
tical Product and Service Solutions program (SPSS® for
Windows, Rel. 10.01 1999).
Results
A total of 200 patients who were admitted to the Cardiac
Care Center at Mount Sinai Hospital were enrolled into
the study. All the physicians approached agreed to have
their patients participate in the survey. Two of the patients
were, eventually, excluded from data analysis due to
incomplete survey data. Of the remaining 198 patients, 94
(47.5%) reported BBT use at some point in their lifetime
and 84 (42%) reported using such products during the
immediate 12 months prior to the survey. Of the 94
patients who used BBT, 32% reported using the products
all the time.
Table 1: Demographic Characteristics of Study Subjects
Users (%) Nonusers (%) p value
Total1 N = 198 94 (47.5) 104(52.5)
Age2 61.4 ± 16.7 58.7 ± 16.3 NSS
Gender NSS
Male 51(54) 67(64)
Female 43(46) 37(36)
Race NSS
White 53(56) 46(44)
Black 19(20) 27(26)
Hispanic 12(13) 18(17)
Other3 10(11) 13(7)
Education 0.0006
< High school 12(13) 28(27)
High school 23(24) 42(40)
Some college 18(19) 12(12)
College Graduate 28(30) 12(12)
Graduate School 13(14) 8(8)
Annual Household Income NSS
< $10,000 17(27) 19(30)
$10,000–$30,000 12(19) 15(23)
$30,000–$50,000 8(13) 14(22)
$50,000–$75,000 15(23) 7(11)
$75,000–$100,000 4(6) 4(6)
> $100,000 5(13) 5(8)
1lifetime use of BBT;2 mean age ± standard deviation (range);
3Asian/Pacific Islander/IndianBMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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Demographic characteristics
The demographic and socioeconomic characteristics of
the total sample are presented in Table 1. The mean age of
surveyed participants was 60.0 ± 16.5 years, and their ages
were normally distributed ranging from 19 to 102 years of
age. The overall sample consisted of 118 (59.6%) men
and 80 (40.4%) women.
Overall, education level significantly influenced the use of
BBT, p = 0.0006. Among users, more patients had college
degrees (28 [30%]) as compared with nonusers, (12
[12%], p = 0.003). In contrast, 42 (40%) nonusers fin-
ished high school versus 23 (24%) of users, p = 0.023.
There were no significant differences between users and
nonusers in other demographic variables.
Cardiovascular diseases, other medical conditions and 
medications used
The distribution of cardiovascular and noncardiovascular
diseases reported by the sample is presented in Table 2.
The mean number of disease diagnoses carried by users
and nonusers were 4 (range 1 – 10) and 3 (range 1 – 8),
respectively, p = 0.723, while the mean number of cardio-
vascular diagnoses for users versus nonusers were 3 (range
1 – 6) and 3 (range 1 – 5), respectively, p = 0.134. The
most common cardiovascular conditions diagnosed in
users and nonusers were hypertension, 56 (24%) and 65
(27%), followed closely by coronary heart disease, 45
(19%) and 54 (18%), respectively. Distribution of other
cardiovascular diseases between users and nonusers was
similar as well. Similarly, the mean number of noncardi-
ovascular diagnoses reported by users and nonusers of
BBT were not significantly different: 2 (range 1 – 5) and 1
(range 1 – 5), respectively, p = 0.288.
The mean number of traditional prescription and nonpre-
scription medications taken by the users of BBT (7 [range
1–15]) and nonusers (7 [range 0–18]) was not signifi-
cantly different, p = 0.445. The most common cardiovas-
cular medications prescribed for both users and nonusers
were diuretics (71%, 73%), followed by aspirin (56%,
43%) and beta-blockers (49%, 50%). The cardiovascular
and noncardiovascular medications taken by both groups
were not different.
Types and patterns of BBT use
The BBT products utilized by cardiovascular patients are
presented in Table 3. The mean number of BBT products
utilized by cardiovascular patients was two. Vitamin E
(41, [44%]) was the most commonly utilized BBT, fol-
lowed by vitamin C, (30 [32%]). The prevalence of the
remaining BBT is summarized in Table 3.
Table 2: Distribution of Cardiovascular and Noncardiovascular Diseases
Users Nonusers p value
Average number of diseases 4 3 NSS
Range 1 – 10 1 – 8
Average number of cardiovascular diseases 3 3 NSS
Arrhythmia 25 32
Congestive Heart Failure 38 52
Coronary Heart Disease 45 54
Hyperlipidemia 31 43
Hypertension 56 65
Other1 12 14
Post-heart Transplant Recipient 1 2
Thromboembolic Disease 13 16
Valvular Heart Disease 11 14
Average number of noncardiovascular diseases 2 1 NSS
Arthritis 25 17
Cancer 3 4
Diabetes Mellitis 33 33
Gastrointestinal Disease 19 13
Hypothyroidism 5 11
Nervous System Disorder 8 9
Ocular Disease 6 6
Other2 30 13
Pulmonary Disease 12 13
Renal Disease 7 12
1aneurysm, peripheral vascular disease, infective endocarditis, pulmonary hypertension, congenital heart disease;
2allergic rhinitis, scleroderma, systemic lupus erythematosis, Raynaud's disease, benign prostatic disease, osteoporosisBMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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The patients reported that their physicians were aware of
their BBT use in 60% of the instances and pharmacists
were aware in 32% of the cases. Only 33% of users
reported that they were asked about BBT use during a his-
tory/physical examination by a health care professional.
The patients were not surveyed about their pharmacists'
assessments of BBT use.
Perceived benefits and attitudes towards BBT
A greater percentage of users (74.5%) of BBT reported that
they believed these products to be safe substances as com-
pared with nonusers (26.2%), p < 0.001. Likewise, signif-
icantly more users believed that BBT was effective (70.2%)
compared to nonusers (30.1%), p < 0.001. More nonusers
(72%) than users (45%) did not know whether BBT prod-
ucts work better, as well as, or worse than traditional med-
ications, p < 0.001. More users than nonusers believed
Table 3: All Biological Based Therapies Utilized by Cardiovascular Patients (at any time)
Product Number Reasons for Use (per patient)
AA#5 (anti-arthritis) 1 treat arthritis
Acidophillus 1 health
Aloe vera 4 headache, stomach gas, skin pigmentation
Atomic Drops 1 treat headache
Bee Pollen 1 prevent cold
Beta carotene 5 maintain good health, energy, improve heart contraction
Bioflavinoid 1 bone health instructed by chiropractor
Calcium 19 supplement, prevent osteoporosis, improve heart function
Chamomile 2 stomach ache, improve heart condition
Chromium picolante 2 supplement for heart condition, muscle strength
Coenzyme Q 10 11 improve heart contraction, supplement to diet
Dexatrim 1 weight lost
DHEA1 1s u p p l e m e n t
Echinacea 5 prevent or treat cold, flu, stay healthy, boost immune system
Fish Oil 12 decrease cholesterol, maintain circulation and good health, scleroderma
Folic Acid 3 supplement, help with heart condition, sickle cell anemia
Garlic 5 decrease cholesterol, help maintain good health
Ginkgo biloba 5 antioxidant, enhance memory, energy
Ginseng 4 increase energy, stamina, virility
Glucosamine/chondroitin 10 treat arthritis, decrease joint pain
Golden seal 1 body cleaner
Grapeseed oil 1 preserve health
Green tea 3 decrease cholesterol, improve circulation
Mixed herbal tea 1 Sooth stomach upset, anxiety
Insulin leaf tea 1 diabetes
Iron supplement 4 anemia, increase energy
Lecithin 2 improve heart condition and circulation, decrease cholesterol
Alpha-Linolenic acid 1 improve heart condition
Magnesium 8 supplement, antioxidant, improve metabolism, improve heart function
Multivitamins 24 supplement, energy, sickle cell anemia
Primrose oil 1 scleroderma
Saint John's Wart 1 depression
Saw palmetto 1 for prostate health
Selenium 4 antioxidant, supplement, improve heart condition
Strong bark 1 help with heart condition
Valerian 4 decrease anxiety, improve sleep, to decrease blood pressure
Vitamin B complex 17 supplement, improve heart condition, decrease leg cramps, energy
Vitamin B12 2 supplement, anemia
Vitamin C 30 antioxidant, supplement, help with heart condition, improve circulation, strengthen immune system, 
prevent or treat cold
Vitamin E 41 antioxidant, supplement, help with heart condition, increase energy, decrease cholesterol, improve 
circulation, thin blood, treat hypertension
Yohimbine 1 increase energy, stamina, virility
Zinc 4 supplement
1dehydroepiandrosteroneBMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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that BBT works as well as traditional medications (30.9%
versus 9.7%, p < 0.001). Concerning adverse effects, more
users (44.7%) of BBT than nonusers (17.5%) believed
that BBT causes fewer side effects than traditional medica-
tions, p < 0.001. At the same time, 32.2% of users and
62.1% of nonusers did not know whether BBT causes
more or fewer side effects than traditional prescription
medications, p < 0.001.
Potential drug-BBT interactions
Examination of patients' prescription and nonprescrip-
tion medication profiles and BBT utilized, revealed 42
potential drug-BBT interactions. The onset of the interac-
tion and the degree of severity were classified according to
that used by the MicroMedex HealthCare Series Inte-
graded Index [28] and the published literature [29-43].
Suspected or potential interactions were communicated
Table 4: Potential Drug-Biological Based Therapies Interactions & Management
Medication Alternative 
Pharmacotherapy 
Product
Potential Interaction and Management Number of 
Patients
Onset28* Level of 
Severity28
Warfarin Green tea Green tea may antagonize warfarin effects. Monitor 
INR.
1 Delayed Moderate
Warfarin Coenzyme Q 10 Coenzyme Q 10 may have procoagulant effects and may 
decrease response to warfarin.
Monitor INR.
2 Delayed Moderate
Warfarin Vitamin E Vitamin E may potentiate warfarin effects. Monitor INR 
and signs and symptoms of bleeding.
5 Delayed Moderate
Warfarin Garlic Garlic has antiplatelet effects, and risk of bleeding may 
be increased.
Monitor INR and signs and symptoms of bleeding.
1 Delayed Major
Warfarin Ginkgo biloba Ginkgo inhibits platelet aggregation, risk of bleeding may 
be increased.
Monitor INR and signs and symptoms of bleeding
2 Delayed Major
Warfarin Fish oils Concomitant use of warfarin and fish oils may increase 
risk of bleeding.
Monitor INR and signs and symptoms of bleeding.
1 Not specified Not specified
Aspirin Vitamin E Coadministration of vitamin E and aspirin may increase 
the risk of bleeding. Monitor for signs and symptoms of 
bleeding
16 Not Specified Not specified
Aspirin Garlic Additive antiplatelet effects may occur with 
coadministration of garlic and aspirin, risk of bleeding 
may be increased. Monitor for signs and symptoms of 
bleeding
1 Delayed Moderate
Aspirin Fish oils Concomitant use of aspirin and fish oils may increase 
risk of bleeding.
Monitor for signs and symptoms of bleeding
3 Not specified Not specified
Aspirin Ginko biloba Ginkgo inhibits platelet aggregation; risk of bleeding may 
be increased.
Monitor for signs and symptoms of bleeding.
1 Delayed Major
Clopidogrel Vitamin E Concomitant use of vitamin E and clopidogrel may 
increase the risk of bleeding. Monitor for signs and 
symptoms of bleeding
5 Not specified Not specified
Clopidogrel Garlic Additive antiplatelet effects may occur, risk of bleeding 
may be increased. Monitor for signs and symptoms of 
bleeding
1 Delayed Major
Clopidogrel Coenzyme Q Coenzyme Q 10 may have procoagulant effects, may 
partially antagonize antiplatelet effect of clopidogrel.
1 Not specified Not specified
Insulin Insulin leaf Enhanced hypoglycemic effects.
Patient was advised to discontinue insulin leaf while 
receiving insulin for glycemic control.
1 Delayed Moderate
Paroxetine Saint John's Wort Saint John's Wort induces cytochrome P450 3A4 
enzyme and has mechanism of action similar to 
serotonin reuptake inhibitors.
Administering it concomitantly with paroxetine will 
enhance the toxicity of paroxetine. Patient was advised 
to discontinue the use of Saint John's Wort
1R a p i d S e v e r e
INR = International Normalized Ratio
* Delayed onset of interactions occurs after multiple doses of both agents.BMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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to the patients and their primary physicians. The most
common interaction identified was coadministration of
aspirin and vitamin E (16 cases) that could potentially
result in an increased risk of bleeding due to additive inhi-
bition of platelet aggregation [29-31]. Similar effects may
result from coadministration of clopidogrel and vitamin
E; this potential interaction was recognized in five cases
[31]. Five instances of potential interaction between war-
farin and vitamin E were identified and close monitoring
of the International Normalized Ratio (INR) was recom-
mended [32-34]. A list of other potential drug-BBT inter-
actions that were identified is presented in Table 4.
Discussion
Despite a wide array of available BBT for cardiovascular
conditions, studies evaluating the prevalence of their
usage are limited. A review of the literature at the time of
study initiation (January 2001) and more recently (June
2004) identified five studies in this area, and only a few
included a broad spectrum of cardiovascular disease
patients [21-25].
Wood et al. conducted a telephone survey in 107 patients
randomly selected from the "Improving Cardiovascular
Outcomes in Nova Scotia" database [24]. A majority of
patients (64%) in this study utilized CAM. Ackman and
colleagues evaluated the patterns of BBT use by patients
with congestive heart failure (CHF) [21]. Out of 180 CHF
patients, 59% used vitamins and minerals and 38% used
herbal or health food products. Liu and associates evalu-
ated the prevalence of CAM used in 263 patients undergo-
ing cardiovascular surgery [22]. Seventy-five percent of
respondents utilized CAM including vitamins (53.6%),
nutritional therapy (17.1%) and herbs (9.9%). Compared
with non-CAM users, users were older (p = 0.027),
belonged to the Caucasian racial group, (p = 0.001) and
had a higher level of education (p = 0.017). Additionally,
the evaluation of attitudes towards the effectiveness of
CAM revealed that users were more likely to believe that
CAM would work in a complimentary manner with
conventional medical treatments, p < 0.05. Furthermore,
more users than nonusers believed that CAM would pro-
mote general health and wellness, p < 0.05. Of the
patients surveyed, only 17% reported discussing CAM
with their medical doctors. Another recent study evalu-
ated the use of CAM among 246 patients attending a car-
diac clinic prior to cardiac surgery [23]. A total of 182
(80.9%) patients used CAM, and 12.9% utilized megavi-
tamins. Another study, conducted in Canada, focused on
the use of over-the-counter medications and herbal prod-
ucts among patients with cardiac diseases, the majority of
whom were diagnosed with coronary artery disease (74%)
[25]. The authors reported that 23% of the patients used
multivitamin or multivitamin/mineral products. Overall,
the results of these five studies confirm a high prevalence
of all kinds of CAM used, including BBT among patients
with cardiovascular diseases.
Biological based therapy used by cardiovascular patients
In our study, the lifetime prevalence of BBT use in the
sample of 198 cardiovascular patients was 47.5%, which
is very similar to the results reported by Eisenberg and col-
leagues in the general population (42%) [3]. Compari-
sons with other investigations of alternative medicine use
in cardiovascular patients are difficult to make due to the
various definitions of "alternative medicine" [21-25].
Some studies included items such as alternative proce-
dures including acupuncture, while others included
"pharmacotherapy" only (herbs, BBT, CAM and nutri-
tional supplements). In addition, certain studies looked at
only one cardiovascular disease while others looked at a
broad range of patients with multiple diseases. Further-
more, different studies also used different measurements
of incidence and prevalence; i.e., some investigators
focused on lifetime use, others reviewed the previous 12-
month history only, yet others limited their findings to
BBT use in the 14 days prior to the investigation.
Regardless, results indicated that a high percentage of
patients with cardiovascular diseases are taking some kind
of BBT (almost one out of every two patients). Health care
professionals need to be aware of these findings and rou-
tinely inquire about BBT use by patients when taking a
medication history.
Similar to Ackman's study [21], the most frequently uti-
lized BBT in the present study of cardiovascular patients
was vitamin E, (41 [43.6%]). The popularity of vitamin E
among cardiovascular patients is not surprising due to the
alleged benefits of this vitamin in heart disease from early
literature [12-14], and its relative availability in pharma-
cies, health food stores and supermarkets. As was the case
with vitamin E, the use of vitamin C in the current inves-
tigation, (30 [31.9%]) was similar to previously reported
results, being the second most common product utilized
by cardiovascular patients [21].
Similar to other studies [1,3,6,21], the current study con-
firmed that based on the patients' reports, a high percent-
age of physicians (40%) and pharmacists (68%) were not
aware of BBT used by cardiovascular patients. Use of BBT
by the patients in this study was not routinely discussed
with health care providers during medical history evalua-
tion (33%). This is an alarming but not an isolated find-
ing. On average, cardiovascular patients consumed 7
(range, 1 – 18) prescribed medications, and 2 (range, 1 –
12) BBT products. Considering the complex medical treat-
ment received by cardiovascular patients, addition of
unmonitored BBT to the patients' regimens may place the
users of these therapies at a greater risk for the develop-
ment of adverse events and interactions with prescribedBMC Complementary and Alternative Medicine 2005, 5:4 http://www.biomedcentral.com/1472-6882/5/4
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medications. As addressed by this analysis, 42 potential
drug-BBT interactions were identified.
Demographics impact on biological based therapy use in 
cardiovascular patients
Among the demographic variables collected in this analy-
sis, no parameter other than the level of education had a
significant impact on whether patients used BBT. The
present investigation revealed that the education level
among users (63% received some college or college and
graduate school education) of BBT was higher than that of
the nonusers (32%), p < 0.001. This finding has also been
reported in other studies [3,6]. Higher level of education
has been shown to significantly influence the use of alter-
native products and services [3]. Education level is some-
times directly related to economic status, thus the patients
may have more resources to spend on BBT. Similarly, bet-
ter-educated consumers may be more likely to be exposed
to various less conventional forms of healthcare reading
about their illnesses and treatment options. Educated
patients also might be less inclined to accept their physi-
cians' knowledge and expertise, and may seek other treat-
ment options.
Perceived safety and efficacy of BBT
The majority of BBT users (as compared to nonusers) in
the current investigation believed that BBT products are
safe, effective and cause fewer side effects as compared to
prescription medications. These results are consistent with
the findings by other investigators [6,21], supporting a
logical conclusion that patients who believe that BBT are
safe and effective, are more likely to use them.
Study limitations
Several limitations of the study need to be addressed.
Those that are intrinsically related to survey data collec-
tion in general include potential bias of responders and
nonresponders. Since participation in this study was vol-
untary, patients who chose to participate in the study may
be more motivated and knowledgeable about the subject
of BBT as compared to those who refused to participate.
Therefore, the results of this study may not be applicable
to the entire cardiovascular patient population. Also, a
cross-sectional nature of this study precludes drawing any
definitive conclusions regarding cause and effect relation-
ships. For example, one cannot definitively conclude that
more education will significantly effect one's decision to
take BBT because other factors such as exposure to these
types of products may have influenced more educated
consumers to take these products.
As with other surveys, recall bias cannot be eliminated as
data collection relied on patients' self-report, rather than
objectively documenting BBT use. Additionally, with sur-
veys there is always a possibility of misunderstanding the
questions and responses, miscommunication between the
interviewer and the patients, and inaccurate recording of
the information. The majority of the survey collected fac-
tual information (i.e., demographics and BBT usage his-
tory). However, the questions that evaluated patients'
perception on the safety and efficacy of conventional
medicine and BBT were not validated.
This study was conducted in a large urban inner city hos-
pital; the results may not be extrapolated to other cities or
clinical settings. Another limitation may be the exclusion
of non-English speaking patients, which may be particu-
larly important since there are certain ethnic groups who
are documented to use more BBT than are other ethnic
groups (e.g., persons of or from Chinese descent utilize
traditional Chinese herbal medications). Finally, termi-
nology varies greatly in the published literature. Some
authors use the term CAM in all instances, others differen-
tiate CAM from BBT, etc. As a result, it is very difficult to
compare published reports with certainty.
Conclusion
In recent years, the interest of using BBT in disease man-
agement has increased dramatically in the medical and
layman communities. The amount of valid scientific
research in this area of therapy continues to increase. Yet,
there are still many unknowns concerning BBT, especially
in the area of adverse effects and drug interactions. The
finding of a high prevalence of BBT (47.5%) use among
cardiovascular patients and the lack of communication
between patients and their physicians/pharmacists should
be addressed by the health care community. Higher edu-
cation level, as shown in the present study and other pre-
vious investigations [1,3,6,22], is associated with an
increased use of BBT, but it does not necessarily mean that
these patients are aware of the potential detrimental
effects of BBT, as demonstrated in the current study. In
cardiovascular patients, the perceived effectiveness and
safety of BBT, and assumed lack of side effects of these
products as opposed to traditional medications, high-
lights an area for further education. A high incidence of
potential drug-BBT interactions was also identified in this
study (42 interactions in 94 users). Given that the use of
BBT can have a direct effect on patient care, and users of
these therapies do not always voluntarily report their use
of these products to their providers, health care profes-
sionals need to inquire about BBT use routinely. Collect-
ing complete patient histories and educating patients
about potential dangers and possibilities of adverse effects
and interactions between prescription medications and
BBT (or other CAM) will lead to better overall patient care.
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